Drug Trial Radar · NCT05899673
An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
200
Actual
Start
Aug 8, 2023
Primary completion
May 2, 2033
Study completion May 2, 2033
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jun 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The liver produces a protein called alpha-1 antitrypsin (AAT) which is released into the bloodstream. In some people, the liver makes an abnormal version of AAT, called Z-AAT. Z-AAT builds up in liver cells, and over time may lead to liver scarring (fibrosis), severe liver scarring (cirrhosis), and eventually end-stage liver disease. Fazirsiran is a medicine that reduces the production of the abnormal Z-AAT protein and its build-up in the liver. The main aim of this study is to learn if fazirsiran is safe during long-term use in people with liver disease caused by the abnormal Z-AAT protein. People who have taken part in previous fazirsiran studies (AROAAT2001 \[NCT03945292\], AROAAT2002 \[NCT03946449\] , TAK-999-3001 \[NCT05677971\], or TAK-999-3002 \[NCT06165341\]) can continue to receive fazirsiran in this study. Participants will receive fazirsian every 3 months, along with health checks, as long as they participate in this study, the study is ongoing or until health authorities in their country approve fazirsiran to be publicly available. The study may also provide information on whether fazirsiran has a long-term effect in reducing liver fibrosis or slowing down the progression of liver fibrosis in people with liver disease due to the abnormal Z-AAT protein.
Conditions
- Alpha1-Antitrypsin Deficiency
Interventions
Fazirsiran InjectionDrug
Fazirsiran will be injected subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)Time frame: From start of study drug administration (in current study) up to End of study (EOS) (current study [up to 10 years])
- Number of Participants With Clinically Significant Changes From Baseline in Pulmonary Function ParametersTime frame: Baseline (current study), up to EOS (current study up to 10 years])
- Number of Participants With Clinically Significant Changes in Vital SignsTime frame: From start of study drug administration (in current study) up to EOS (current study [up to 10 years])
- Number of Participants With Clinically Significant Changes in Laboratory ParametersTime frame: From start of study drug administration (in current study) up to EOS (current study [up to 10 years])
Locations
10 sites in 5 countries. Site status is shown where the registry gives one.
UCSD Altman Clinical and Translational Research Institute
La Jolla, California
Stanford Medicine Outpatient Center
Redwood City, California
UF Clinical and Translational Science Institute
Gainesville, Florida
University Of Iowa Hospitals And Clinics
Iowa City, Iowa
Medical University of South Carolina - Hollings Cancer Center - PPDS
Charleston, South Carolina
Medizinische Universitat Wien (Medical University of Vienna)
Vienna, Austria
Universitätsklinikum der RWTH Aachen
Aachen, North Rhine-Westphalia, Germany
Hospital Nélio Mendonça
Funchal, Portugal
Addenbrooke's Hospital
Cambridge, United Kingdom
Royal Infirmary of Edinburgh - PPDS
Edinburgh, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.